For a growing number of the world’s major life science companies, the answer is Denmark – a global player in life sciences, the home of a world-leading healthcare industry and a country with a strong national health system, reliable and effective public authorities and a dynamic business environment. Today, Denmark conducts the most clinical trials per capita in Europe.

On top of that, Denmark has a unique access to health data, excellent researchers and much more, which makes Denmark an attractive place for international biotech and pharmaceutical companies wanting to conduct clinical research and trials.

The lunch will begin with a short presentation by Kristoffer Staal Rohrberg, PhD, Chief Consultant and Head of the Phase I cancer unit at Copenhagen University Hospital, focusing on the advantages of Denmark in conducting phase I-III trials.

We also have the privilege of hosting Marianne Pilgaard, CEO of Trial Nation, which is Denmark’s single point of entry for global companies, patient organizations and clinical researchers wishing to conduct clinical trials in Denmark. She will give a brief introduction to Trial Nation and the services they provide.

There will be plenty of opportunities to network with the speakers, Invest in Denmark and an exclusive group of your peers.

In advance of the meeting, please take a few minutes to explore the resume of Kristoffer Staal Rohrberg and Marianne Pilgaard.

If you are interested in a 1-1 meeting prior to or after the roundtable, we are also happy to schedule that.